<DOC>
	<DOCNO>NCT01726049</DOCNO>
	<brief_summary>Aim study investigate whether Sildenafil treatment result reduction pulmonary artery pressure without decrease cardiac output ( CO ) improvement exercise capacity patient heart failure preserve ejection fraction ( HFpEF ) pulmonary hypertension ( PH ) .</brief_summary>
	<brief_title>Sildenafil HFpEF ( Heart Failure With Preserved Ejection Fraction ) PH</brief_title>
	<detailed_description>Rationale : Treatment diastolic leave heart failure challenge task . Compared systolic leave heart failure level evidence know medical treatment regiment low . Sildenafil , phosphodiesterase 5 ( PDE 5 ) inhibitor effective therapy pulmonary arterial hypertension act selective pulmonary vasodilator inhibiting impaired nitric oxide ( NO ) pathway . Reducing pulmonary vascular resistance would primary target treatment diastolic leave heart failure PH . But clinical hemodynamical study evaluate role Sildenafil diastolic heart failure , also call heart failure preserve ejection fraction ( HFpEF ) secondary pulmonary hypertension lacking . Our hypothesis Sildenafil decrease pulmonary artery pressure patient HFpEF pulmonary hypertension . Objective : To investigate whether Sildenafil treatment result hemodynamic improvement improvement exercise capacity patient . Study design : single-center , prospective , randomize , placebo control study . Study population : 52 patient HFpEF PH Intervention : One group receive three time daily 20 mg Sildenafil 2 week follow three time daily 60 mg Sildenafil 10 week . The group receive three time daily 20 mg Placebo , follow 3 time daily 60 mg placebo . Main study parameters/endpoints : Primary objectives 1 . To investigate whether Sildenafil treatment result reduction pulmonary artery pressure ( PAP ) HFpEF patient PH ( investigate invasively right heart catheterization ) . Secondary objective 1 . To investigate whether Sildenafil treatment result reduction wedge pressure HFpEF patient . 2 . To investigate whether Sildenafil treatment result improvenemt cardiac output ( CO ) HFpEF patient . 3 . To investigate whether Sildenafil treatment result improvement exercise capacity patient ( defined change VO2max )</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Heart Failure , Diastolic</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>&gt; 18 year Written inform consent PH secondary diastolic leave heart failure define PAP mean &gt; 25 mmHg Wedge mean &gt; 15 mmHg Normal systolic leave ventricular ( LV ) function echo/nuclear image ( left ventricular ejection fraction ( LVEF ) &gt; =45 % ) New York Heart Association class ( NYHA ) IIIV despite heart failure therapy Severe noncardiac limitation exercise ( severe chronic obstructive pulmonary disease ) Other cause PH besides diastolic heart failure Coronary ischemia recent myocardial infarction ( &lt; 6 month ) Hypotension ( &lt; 90/50 mmHg ) Ongoing nitrate therapy Ongoing therapy citochrome P450 3A4 ( CYP3A4 ) inhibitor ( ketoconazole , erythromycin , cimetidine , clarithromycin , itraconazole , voriconazole protease inhibitor ) CYP3A4 inductor ( carbamacepine , phenytoin , phenobarbital , rifampicin , Sint Janskruid ) . Furthermore patient informed drink grapefruit juice study medication know impact grape fruit pharmacokinetics Sildenafil . Ongoing therapy alpha inhibitor Significant mitral aortic valve dysfunction Severe liver dysfunction Pregnancy Unable read comprehend Dutch language</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>HFpEF</keyword>
	<keyword>PH</keyword>
</DOC>